Comparative Pharmacology
Head-to-head clinical analysis: ALDURAZYME versus PALYNZIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDURAZYME versus PALYNZIQ.
ALDURAZYME vs PALYNZIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALDURAZYME (laronidase) is a recombinant form of human α-L-iduronidase, an enzyme that hydrolyzes terminal α-L-iduronic acid residues in glycosaminoglycans (GAGs) such as dermatan sulfate and heparan sulfate. It replaces the deficient enzyme in patients with mucopolysaccharidosis I (MPS I), reducing lysosomal accumulation of GAGs.
PALYNZIQ (pegvaliase-pqpz) is a recombinant phenylalanine ammonia lyase conjugated to polyethylene glycol. It converts phenylalanine to trans-cinnamic acid and ammonia, reducing blood phenylalanine levels in patients with phenylketonuria.
0.58 mg/kg administered intravenously once weekly.
2.4 mg subcutaneously once daily.
None Documented
None Documented
Terminal half-life: 6–10 minutes (rapid clearance from plasma due to cellular uptake via mannose-6-phosphate receptors); clinical context: clearance is saturable, leading to longer effective half-life at therapeutic doses
Approximately 60–80 hours (terminal half-life); supports weekly dosing regimen.
Renal: negligible; primarily catabolism via peptide hydrolysis; no significant biliary/fecal elimination
Renal (predominantly as intact pegylated enzyme); less than 5% fecal. No active metabolites.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy